

Merck & Co., Inc.  
Form 8-K/A  
February 01, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**(Amendment No. 1)**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **February 1, 2019**

**Merck & Co., Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**New Jersey**

(State or Other Jurisdiction of Incorporation)

**1-6571**

(Commission File Number)

**22-1918501**

(I.R.S. Employer Identification No.)

**2000 Galloping Hill Road, Kenilworth, NJ**  
(Address of Principal Executive Offices)

**07033**  
(Zip Code)

Edgar Filing: Merck & Co., Inc. - Form 8-K/A

Registrant's Telephone Number, Including Area Code (908) 740-4000

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter)

- Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**EXPLANATORY NOTE**

Merck & Co., Inc. (Merck) is filing this Amendment No. 1 to its Current Report on Form 8-K filed with the SEC on February 1, 2019 (the Original Form 8-K), to refurnish Exhibit 99.2 in order to correct a typographical error in Table 3b thereto in which the Global Full Year 2018 sales figure for Isentress / Isentress HD was incorrectly stated to be \$1,410 million rather than \$1,140 million. This Amendment No. 1 is filed solely to refurnish Exhibit 99.2 to correct such typographical error. No changes to the other documents furnished with the Original Form 8-K have been made.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.2      Certain supplemental information not included in the press release

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.2	<u>Certain supplemental information not included in the press release</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.

Date: February 1, 2019

By:

/s/ Karen L. Mealey  
KAREN L. MEALEY  
Assistant Secretary